{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:11:13Z","timestamp":1788851473496,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02133-w","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:29:57Z","timestamp":1788845397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-5001","authenticated-orcid":false,"given":"\u00d6zlem","family":"Co\u015fkun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2133_CR1","doi-asserted-by":"publisher","first-page":"1781797","DOI":"10.3389\/fimmu.2026.1781797","volume":"17","author":"J Ghosh","year":"2026","unstructured":"Ghosh, J., & Chattopadhyay, D. (2026). Immunometabolic control of cytokine production by micronutrients in health, aging, and inflammation. Frontiers in Immunology, 17, 1781797.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"2133_CR2","doi-asserted-by":"publisher","first-page":"uxag014","DOI":"10.1093\/cei\/uxag014","volume":"220","author":"X Ye","year":"2026","unstructured":"Ye, X., Zhang, J., Song, M., Wang, P., Ares, I., Lopez-Torres, B., & Mart\u00ednez, M. A. (2026). Evolving understandings for the roles of CD38 protein in autoimmunity and autoimmune disease. Clinical and Experimental Immunology, 220(1), uxag014.","journal-title":"Clinical and Experimental Immunology"},{"key":"2133_CR3","doi-asserted-by":"publisher","first-page":"1769281","DOI":"10.3389\/fimmu.2026.1769281","volume":"17","author":"AL Horenstein","year":"2026","unstructured":"Horenstein, A. L., Frerichs, K. A., Faini, A. C., Van De Donk, N. W., & Malavasi, F. (2026). Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective. Frontiers in Immunology, 17, 1769281.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"2133_CR4","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00451.2021","volume":"322","author":"JD Zeidler","year":"2022","unstructured":"Zeidler, J. D., Hogan, K. A., Agorrody, G., Peclat, T. R., Kashyap, S., Kanamori, K. S., & Chini, E. N. (2022). The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. American Journal of Physiology-Cell Physiology, 322(3), C521\u2013C545.","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"4","key":"2133_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/cells12040595","volume":"12","author":"M Kitada","year":"2023","unstructured":"Kitada, M., Araki, S. I., & Koya, D. (2023). The role of CD38 in the pathogenesis of cardiorenal metabolic disease and aging, an approach from basic research. Cells, 12(4), 595.","journal-title":"Cells"},{"issue":"11","key":"2133_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s42255-020-00298-z","volume":"2","author":"CC Chini","year":"2020","unstructured":"Chini, C. C., Peclat, T. R., Warner, G. M., Kashyap, S., Espindola-Netto, J. M., de Oliveira, G. C., & Chini, E. N. (2020). CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nature metabolism, 2(11), 1284\u20131304.","journal-title":"Nature metabolism"},{"issue":"6","key":"2133_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/biology14060643","volume":"14","author":"Y Li","year":"2025","unstructured":"Li, Y., Kang, K., Bao, H., Liu, S., Zhao, B., Hu, G., & Wu, J. (2025). Research progress on the interaction between SIRT1 and mitochondrial biochemistry in the aging of the reproductive system. Biology, 14(6), 643.","journal-title":"Biology"},{"issue":"1","key":"2133_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-025-00784-0","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang, Y., Zhu, L., Xu, Y., Liang, L., Liu, L., Chen, X., & Liu, H. (2025). The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomarker Research, 13(1), 75.","journal-title":"Biomarker Research"},{"issue":"8","key":"2133_CR9","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.3390\/ijms23084306","volume":"23","author":"S Takasawa","year":"2022","unstructured":"Takasawa, S. (2022). CD38\u2013cyclic ADP-ribose signal system in physiology, biochemistry, and pathophysiology. International Journal of Molecular Sciences, 23(8), 4306.","journal-title":"International Journal of Molecular Sciences"},{"key":"2133_CR10","doi-asserted-by":"publisher","first-page":"1579924","DOI":"10.3389\/fimmu.2025.1579924","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao, X., Lv, P., Cai, Z., Dong, J., Chen, W., Sun, L., & Yang, R. (2025). Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review. Frontiers in Immunology, 16, 1579924.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"2133_CR11","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00451.2021","volume":"322","author":"JD Zeidler","year":"2022","unstructured":"Zeidler, J. D., Hogan, K. A., Agorrody, G., Peclat, T. R., Kashyap, S., Kanamori, K. S., & Chini, E. N. (2022). The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. American Journal of Physiology-Cell Physiology, 322(3), C521\u2013C545.","journal-title":"American Journal of Physiology-Cell Physiology"},{"key":"2133_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-032-11608-6_5","volume-title":"Suresh I. S. Rattan, Ceren Gezer. Supplements and Drugs for Healthy Longevity","author":"L Yi","year":"2026","unstructured":"Yi, L. (2026). NAD+ and Its Precursors for Health and Longevity. In (Ed.), Suresh I. S. Rattan, Ceren Gezer. Supplements and Drugs for Healthy Longevity (pp. 79\u2013117). Springer Nature Switzerland."},{"issue":"8","key":"2133_CR13","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.3390\/ijms23084306","volume":"23","author":"S Takasawa","year":"2022","unstructured":"Takasawa, S. (2022). CD38\u2013cyclic ADP-ribose signal system in physiology, biochemistry, and pathophysiology. International Journal of Molecular Sciences, 23(8), 4306.","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"2133_CR14","doi-asserted-by":"publisher","first-page":"108248","DOI":"10.1016\/j.jbc.2025.108248","volume":"301","author":"R Madawala","year":"2025","unstructured":"Madawala, R., Banks, J. L., Hancock, S. E., Quek, L. E., Turner, N., & Wu, L. E. (2025). CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide. Journal of Biological Chemistry, 301(3), 108248.","journal-title":"Journal of Biological Chemistry"},{"key":"2133_CR15","first-page":"3","volume-title":"NAADP-mediated Ca2+ signalling. Editors: Christian Wahl-Schott,Martin Biel. Endolysosomal Voltage-Dependent Cation Channels","author":"A Galione","year":"2022","unstructured":"Galione, A., Davis, L. C., Martucci, L. L., & Morgan, A. J. (2022). NAADP-mediated Ca2+ signalling. In (Ed.), Christian Wahl-Schott, Martin Biel. Endolysosomal Voltage-Dependent Cation Channels (pp. 3\u201334). Springer International Publishing."},{"key":"2133_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-981-97-9877-3_17","volume-title":"Biology of Nicotinamide Coenzymes: From Basic Science to Clinical Applications","author":"HD Xu","year":"2025","unstructured":"Xu, H. D., Zhang, D. M., Sun, M. L., & Qin, Z. H. (2025). Nicotinamide Adenine Dinucleotide and Signaling Transduction. In (Ed.), Zhen-Hai Qin. Biology of Nicotinamide Coenzymes: From Basic Science to Clinical Applications (pp. 239\u2013268). Springer Nature Singapore."},{"issue":"3","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00451.2021","volume":"322","author":"JD Zeidler","year":"2022","unstructured":"Zeidler, J. D., Hogan, K. A., Agorrody, G., Peclat, T. R., Kashyap, S., Kanamori, K. S., & Chini, E. N. (2022). The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. American Journal of Physiology-Cell Physiology, 322(3), C521\u2013C545.","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"3","key":"2133_CR18","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.3390\/ijms24032959","volume":"24","author":"B Polj\u0161ak","year":"2023","unstructured":"Polj\u0161ak, B., Kova\u010d, V., \u0160palj, S., & Milisav, I. (2023). The central role of the NAD+ molecule in the development of aging and the prevention of chronic age-related diseases: strategies for NAD+ modulation. International journal of molecular sciences, 24(3), 2959.","journal-title":"International journal of molecular sciences"},{"issue":"1","key":"2133_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12950-025-00457-7","volume":"22","author":"R Mann","year":"2025","unstructured":"Mann, R., Stavrou, V., & Dimeloe, S. (2025). NAD+ metabolism and function in innate and adaptive immune cells. Journal of Inflammation, 22(1), 30.","journal-title":"Journal of Inflammation"},{"issue":"3","key":"2133_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","volume":"88","author":"F Malavasi","year":"2008","unstructured":"Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., & Aydin, S. (2008). Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology. Physiological reviews, 88(3), 841\u2013886.","journal-title":"Physiological reviews"},{"issue":"1","key":"2133_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1196\/annals.1322.021","volume":"1028","author":"A De Flora","year":"2004","unstructured":"De Flora, A., Zocchi, E., Guida, L., Franco, L., & Bruzzone, S. (2004). Autocrine and paracrine calcium signaling by the CD38\/NAD+\/cyclic ADP-ribose system. Annals of the New York Academy of Sciences, 1028(1), 176\u2013191.","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"20","key":"2133_CR22","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.3390\/molecules25204844","volume":"25","author":"AL Horenstein","year":"2020","unstructured":"Horenstein, A. L., Faini, A. C., Morandi, F., Bracci, C., Lanza, F., Giuliani, N., & Malavasi, F. (2020). The circular life of human CD38: from basic science to clinics and back. Molecules, 25(20), 4844.","journal-title":"Molecules"},{"issue":"21","key":"2133_CR23","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1074\/jbc.RA118.002113","volume":"293","author":"C Fang","year":"2018","unstructured":"Fang, C., Li, T., Li, Y., Xu, G. J., Deng, Q. W., Chen, Y. J., & Zhao, Y. J. (2018). CD38 produces nicotinic acid adenosine dinucleotide phosphate in the lysosome. Journal of Biological Chemistry, 293(21), 8151\u20138160.","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"2133_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4331\/wjbc.v5.i1.58","volume":"5","author":"W Wei","year":"2014","unstructured":"Wei, W., Graeff, R., & Yue, J. (2014). Roles and mechanisms of the CD38\/cyclic adenosine diphosphate ribose\/Ca2\u2009+\u2009signaling pathway. World journal of biological chemistry, 5(1), 58.","journal-title":"World journal of biological chemistry"},{"key":"2133_CR25","doi-asserted-by":"publisher","first-page":"703326","DOI":"10.3389\/fimmu.2021.703326","volume":"12","author":"TF Walseth","year":"2021","unstructured":"Walseth, T. F., & Guse, A. H. (2021). NAADP: from discovery to mechanism. Frontiers in Immunology, 12, 703326.","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"2133_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41583-025-01016-y","volume":"27","author":"LG Carvalhais","year":"2026","unstructured":"Carvalhais, L. G., Kole, K., & Kuijpers, M. (2026). The diverse forms and roles of the neuronal endoplasmic reticulum. Nature Reviews Neuroscience, 27(4), 260\u2013277.","journal-title":"Nature Reviews Neuroscience"},{"key":"2133_CR27","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","volume":"11","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero, Z. L., Wilson, Z., Nava, P., & Guerau-de-Arellano, M. (2020). CD38: an immunomodulatory molecule in inflammation and autoimmunity. Frontiers in immunology, 11, 597959.","journal-title":"Frontiers in immunology"},{"key":"2133_CR28","first-page":"99","volume":"75","author":"S Deaglio","year":"2000","unstructured":"Deaglio, S., Mallone, R., Baj, G., Arnulfo, A., Surico, N., Dianzani, U., & Malavasi, F. (2000). CD38\/CD31, a receptor\/ligand system ruling adhesion and signaling in human leukocytes. Chemical immunology, 75, 99\u2013121.","journal-title":"Chemical immunology"},{"issue":"1","key":"2133_CR29","first-page":"6630295","volume":"2021","author":"S Dwivedi","year":"2021","unstructured":"Dwivedi, S., Rend\u00f3n-Huerta, E. P., Ortiz-Navarrete, V., & Monta\u00f1o, L. F. (2021). CD38 and regulation of the immune response cells in cancer. Journal of Oncology, 2021(1), 6630295.","journal-title":"Journal of Oncology"},{"issue":"12","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cells8121527","volume":"8","author":"F Morandi","year":"2019","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019). CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies. Cells, 8(12), 1527.","journal-title":"Cells"},{"key":"2133_CR31","doi-asserted-by":"publisher","first-page":"1569707","DOI":"10.3389\/fonc.2025.1569707","volume":"15","author":"L Mettivier","year":"2025","unstructured":"Mettivier, L., De Novellis, D., Della Corte, A. M., Serio, B., Pezzullo, L., Guariglia, R., & Selleri, C. (2025). CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience. Frontiers in oncology, 15, 1569707.","journal-title":"Frontiers in oncology"},{"issue":"21","key":"2133_CR32","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/cancers15215160","volume":"15","author":"M Cerreto","year":"2023","unstructured":"Cerreto, M., Fo\u00e0, R., & Natoni, A. (2023). The role of the microenvironment and cell adhesion molecules in chronic lymphocytic leukemia. Cancers, 15(21), 5160.","journal-title":"Cancers"},{"issue":"1","key":"2133_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","volume":"22","author":"V Bocuzzi","year":"2024","unstructured":"Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D\u2019Huyvetter, M., & Marcion, G. (2024). CD38 as theranostic target in oncology. Journal of Translational Medicine, 22(1), 998.","journal-title":"Journal of Translational Medicine"},{"issue":"20","key":"2133_CR34","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","volume":"12","author":"K Bisht","year":"2023","unstructured":"Bisht, K., Fukao, T., Chiron, M., Richardson, P., Atanackovic, D., Chini, E., & Malavasi, F. (2023). Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer medicine, 12(20), 20332\u201320352.","journal-title":"Cancer medicine"},{"issue":"5","key":"2133_CR35","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022). Anti CD38 monoclonal antibodies for multiple myeloma treatment. Human Vaccines & Immunotherapeutics, 18(5), 2052658.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"2133_CR36","doi-asserted-by":"publisher","first-page":"1745988","DOI":"10.3389\/fimmu.2026.1745988","volume":"17","author":"N Dutta","year":"2026","unstructured":"Dutta, N., Halder, N., Chini, E. N., Kim, S., & Manna, A. (2026). Regulating the regulators via targeting CD38 in the tumor microenvironment. Frontiers in Immunology, 17, 1745988.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"2133_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/joah.joah_92_25","volume":"17","author":"AK Gatea","year":"2026","unstructured":"Gatea, A. K., & Al-Jabory, M. A. (2026). The Landscape of Leukocyte-associated Immunoglobulin-like Receptor-1\/CD38 Expression in Newly Diagnosed Chronic Lymphocytic Leukemia Patients: Insights into Clinical and Immunehematological Profiles. Journal of Applied Hematology, 17(1), 11\u201318.","journal-title":"Journal of Applied Hematology"},{"issue":"2","key":"2133_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.32604\/biocell.2025.074128","volume":"50","author":"P Piwowarczyk","year":"2026","unstructured":"Piwowarczyk, P., Wo\u015b, J., Szyma\u0144ska, A., Chocholska, S., Tomczak, W., Roli\u0144ski, J., & Bojarska-Junak, A. (2026). Immunoregulatory Subpopulations of iNKT Cells and Myeloid-Derived Suppressor Cells in Chronic Lymphocytic Leukemia: Implications for Disease Progression and Immune Evasion. Biocell : Official Journal Of The Sociedades Latinoamericanas De Microscop\u00eda Electronica. . Et. Al, 50(2), 12.","journal-title":"Biocell : Official Journal Of The Sociedades Latinoamericanas De Microscop\u00eda Electronica. . Et. Al"},{"issue":"2","key":"2133_CR39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4049\/jimmunol.1401350","volume":"194","author":"S B\u00fcrgler","year":"2015","unstructured":"B\u00fcrgler, S., Gimeno, A., Parente-Ribes, A., Wang, D., Os, A., Devereux, S., & Munthe, L. A. (2015). Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell\u2013derived IFN-\u03b3 by a T-bet\u2013dependent mechanism. The Journal of Immunology, 194(2), 827\u2013835.","journal-title":"The Journal of Immunology"},{"issue":"4","key":"2133_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cells14040309","volume":"14","author":"L Lin","year":"2025","unstructured":"Lin, L., Roccuzzo, G., Yakymiv, Y., Marchisio, S., Ortolan, E., Funaro, A., & Quaglino, P. (2025). The CD39\/CD73\/Adenosine and NAD\/CD38\/CD203a\/CD73 Axis in Cutaneous T-Cell Lymphomas. Cells, 14(4), 309.","journal-title":"Cells"},{"key":"2133_CR41","doi-asserted-by":"publisher","first-page":"837230","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun, C., Wang, B., & Hao, S. (2022). Adenosine-A2A receptor pathway in cancer immunotherapy. Frontiers in immunology, 13, 837230.","journal-title":"Frontiers in immunology"},{"issue":"1","key":"2133_CR42","doi-asserted-by":"publisher","first-page":"2400429","DOI":"10.1080\/2162402X.2024.2400429","volume":"13","author":"VV Vijayan","year":"2024","unstructured":"Vijayan, V. V., Nair, P. G., & Gujar, S. (2024). Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy. Oncoimmunology, 13(1), 2400429.","journal-title":"Oncoimmunology"},{"issue":"9","key":"2133_CR43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1158\/2159-8290.CD-18-0798","volume":"8","author":"D Mittal","year":"2018","unstructured":"Mittal, D., Vijayan, D., & Smyth, M. J. (2018). Overcoming acquired PD-1\/PD-L1 resistance with CD38 blockade. Cancer Discovery, 8(9), 1066\u20131068.","journal-title":"Cancer Discovery"},{"issue":"22","key":"2133_CR44","doi-asserted-by":"publisher","first-page":"13686","DOI":"10.3390\/ijms232213686","volume":"23","author":"R Bergantim","year":"2022","unstructured":"Bergantim, R., Peixoto da Silva, S., Pol\u00f3nia, B., Barbosa, M. A., Albergaria, A., Lima, J., & Vasconcelos, M. H. (2022). Detection of measurable residual disease biomarkers in extracellular vesicles from liquid biopsies of multiple myeloma patients\u2014A proof of concept. International Journal of Molecular Sciences, 23(22), 13686.","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"2133_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4049\/jimmunol.1003884","volume":"187","author":"A Clayton","year":"2011","unstructured":"Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011). Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. The Journal of Immunology, 187(2), 676\u2013683.","journal-title":"The Journal of Immunology"},{"key":"2133_CR46","doi-asserted-by":"crossref","unstructured":"Xie, Q. H., Zheng, J. Q., Ding, J. Y., Wu, Y. F., Liu, L., Yu, Z. L., & Chen, G. (2022). Exosome-mediated immunosuppression in tumor microenvironments. Cells, 11(12), 1946.","DOI":"10.3390\/cells11121946"},{"key":"2133_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mce.2016.11.003","volume":"455","author":"CC Chini","year":"2017","unstructured":"Chini, C. C., Tarrag\u00f3, M. G., & Chini, E. N. (2017). NAD and the aging process: Role in life, death and everything in between. Molecular and cellular endocrinology, 455, 62\u201374.","journal-title":"Molecular and cellular endocrinology"},{"key":"2133_CR48","doi-asserted-by":"crossref","unstructured":"Gay, F., Zamagni, E., Cole, C. E., Scheid, C., Hultcrantz, M., Chorazy, J., \u2026 Iida,S. (2025). Clinical outcomes associated with anti-CD38-based retreatment in relapsed\/refractory multiple myeloma: a systematic literature review. Frontiers in oncology, 15, 1550644.","DOI":"10.3389\/fonc.2025.1550644"},{"key":"2133_CR49","doi-asserted-by":"crossref","unstructured":"Horenstein, A. L., Faini, A. C., Morandi, F., Ortolan, E., Storti, P., Giuliani, N.,\u2026 Malavasi, F. (2025). Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects. Frontiers in Immunology, 16, 1519300.","DOI":"10.3389\/fimmu.2025.1519300"},{"key":"2133_CR50","doi-asserted-by":"publisher","first-page":"1747723","DOI":"10.3389\/fonc.2026.1747723","volume":"16","author":"Y Jin","year":"2026","unstructured":"Jin, Y., Wang, S., Fang, Z., & Qian, S. (2026). Case Report: Simultaneous chronic lymphocytic leukemia and macrofocal multiple myeloma with extramedullary plasmacytoma. Frontiers in Oncology, 16, 1747723.","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"2133_CR51","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.sjbs.2023.103920","volume":"31","author":"MS Abduh","year":"2024","unstructured":"Abduh, M. S. (2024). An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi Journal of Biological Sciences, 31(2), 103920.","journal-title":"Saudi Journal of Biological Sciences"},{"key":"2133_CR52","doi-asserted-by":"crossref","unstructured":"Hamada, Y., Sakamoto, T., Yarimizu, D., Uehara, H., Shao, X., Macpherson, T., \u2026 Doi,M. (2026). NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction.bioRxiv, 2026-02.","DOI":"10.7554\/eLife.110696"},{"issue":"12","key":"2133_CR53","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cells8121527","volume":"8","author":"F Morandi","year":"2019","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019). CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies. Cells, 8(12), 1527.","journal-title":"Cells"},{"key":"2133_CR54","doi-asserted-by":"crossref","unstructured":"Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D\u2019Huyvetter, M.,\u2026 Marcion, G. (2024). CD38 as theranostic target in oncology. Journal of Translational Medicine, 22(1), 998.","DOI":"10.1186\/s12967-024-05768-6"},{"key":"2133_CR55","doi-asserted-by":"crossref","unstructured":"Bisht, K., Fukao, T., Chiron, M., Richardson, P., Atanackovic, D., Chini, E., \u2026 Malavasi,F. (2023). Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer medicine, 12(20), 20332\u201320352.","DOI":"10.1002\/cam4.6619"},{"key":"2133_CR56","doi-asserted-by":"publisher","first-page":"1579924","DOI":"10.3389\/fimmu.2025.1579924","volume":"16","author":"X Zhao","year":"2025","unstructured":"Zhao, X., Lv, P., Cai, Z., Dong, J., Chen, W., Sun, L., & Yang, R. (2025). Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review. Frontiers in Immunology, 16, 1579924.","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"2133_CR57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/biom15040587","volume":"15","author":"M Delshad","year":"2025","unstructured":"Delshad, M., Sanaei, M. J., Mohammadi, M. H., Sadeghi, A., & Bashash, D. (2025). Exosomal biomarkers: a comprehensive overview of diagnostic and prognostic applications in malignant and non-malignant disorders. Biomolecules, 15(4), 587.","journal-title":"Biomolecules"},{"key":"2133_CR58","doi-asserted-by":"crossref","unstructured":"Wang, Y. B., Li, T., Wang, F. Y., Yao, X., Bai, Q. X., Su, H. W., \u2026 Tan, R. Z. (2025).The dual role of cellular senescence in macrophages: unveiling the hidden driver of Age-Related inflammation in kidney disease. International Journal of Biological Sciences, 21(2), 632.","DOI":"10.7150\/ijbs.104404"},{"issue":"4","key":"2133_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.33696\/immunology.6.201","volume":"6","author":"W Santiago-Cruz","year":"2024","unstructured":"Santiago-Cruz, W., & Garc\u00eda-Garc\u00eda, F. (2024). T lymphocytes in Aging: CD38 as a Novel Contributor between Inflammaging and Immunosenescence. Journal of Cellular Immunology, 6(4), 148\u2013162.","journal-title":"Journal of Cellular Immunology"},{"key":"2133_CR60","doi-asserted-by":"crossref","unstructured":"Wang, Q., Sun, X., Han, X., Zhang, X., Wang, W., Wang, H., \u2026 Gu, L. (2026). Aging-Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy. MedComm\u2013Oncology, 5(1), e70054.","DOI":"10.1002\/mog2.70054"},{"key":"2133_CR61","doi-asserted-by":"crossref","unstructured":"Chatterjee, S., Daenthanasanmak, A., Chakraborty, P., Wyatt, M. W., Dhar, P., Selvam,S. P., \u2026 Mehrotra, S. (2018). CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response. Cell metabolism, 27(1), 85\u2013100.","DOI":"10.1016\/j.cmet.2017.10.006"},{"issue":"1","key":"2133_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s44324-025-00067-0","volume":"3","author":"K Yusri","year":"2025","unstructured":"Yusri, K., Jose, S., Vermeulen, K. S., Tan, T. C. M., & Sorrentino, V. (2025). The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. Npj Metabolic Health And Disease, 3(1), 26.","journal-title":"Npj Metabolic Health And Disease"},{"key":"2133_CR63","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.dist.2026.100008","volume":"2026","author":"S Sundaresan","year":"2026","unstructured":"Sundaresan, S., & Hottiger, M. O. (2026). Disruption of Myocardial NAD\u207a Balance in Heart Failure: Mechanisms and Therapeutic Opportunities. Disease and Therapeutics, 2026, 100008.","journal-title":"Disease and Therapeutics"},{"key":"2133_CR64","doi-asserted-by":"crossref","unstructured":"Marlein, C. R., Piddock, R. E., Mistry, J. J., Zaitseva, L., Hellmich, C., Horton,R. H., \u2026 Rushworth, S. A. (2019). CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Research, 79(9), 2285\u20132297.","DOI":"10.1158\/0008-5472.CAN-18-0773"},{"key":"2133_CR65","doi-asserted-by":"crossref","unstructured":"Ka, H. I., & Woo, H. G. (2026). Mitochondrial transfer in cancer: mechanisms, immune evasion, and therapeutic opportunities. Genomics & Informatics.","DOI":"10.1186\/s44342-025-00064-1"},{"key":"2133_CR66","doi-asserted-by":"crossref","unstructured":"Guan, F., Wu, X., Zhou, J., Lin, Y., He, Y., Fan, C., \u2026 Xiong, W. (2024). Mitochondrial transfer in tunneling nanotubes\u2014a new target for cancer therapy. Journal of Experimental & Clinical Cancer Research, 43(1), 147.","DOI":"10.1186\/s13046-024-03069-w"},{"key":"2133_CR67","doi-asserted-by":"crossref","unstructured":"Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., \u2026 Uddin,S. (2020). Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. International journal of molecular sciences, 21(14), 5002.","DOI":"10.3390\/ijms21145002"},{"issue":"12","key":"2133_CR68","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/cells8121632","volume":"8","author":"F Costa","year":"2019","unstructured":"Costa, F., Palma, D., B., & Giuliani, N. (2019). CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents. Cells, 8(12), 1632.","journal-title":"Cells"},{"key":"2133_CR69","doi-asserted-by":"crossref","unstructured":"Zheng, M., Zhang, K., Mu, H., Liu, Q., Ge, S., Shan, Y., \u2026 Miao, L. (2026). CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities.Molecular Pharmaceutics.","DOI":"10.1021\/acs.molpharmaceut.5c01232"},{"key":"2133_CR70","doi-asserted-by":"crossref","unstructured":"Nijhof, I. S., Casneuf, T., Van Velzen, J., van Kessel, B., Axel, A. E., Syed, K.,\u2026 van de Donk, N. W. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, the Journal of the American Society of Hematology, 128(7), 959\u2013970.","DOI":"10.1182\/blood-2016-03-703439"},{"key":"2133_CR71","doi-asserted-by":"crossref","unstructured":"Zannetti, B. A., Faini, A. C., Massari, E., Geuna, M., Maffini, E., Poletti, G., \u2026Lanza, F. (2020). Novel insights in anti-CD38 therapy based on CD38-receptor expression and function: the multiple myeloma model. Cells, 9(12), 2666.","DOI":"10.3390\/cells9122666"},{"issue":"1","key":"2133_CR72","first-page":"6630295","volume":"2021","author":"S Dwivedi","year":"2021","unstructured":"Dwivedi, S., Rend\u00f3n-Huerta, E. P., Ortiz-Navarrete, V., & Monta\u00f1o, L. F. (2021). CD38 and regulation of the immune response cells in cancer. Journal of Oncology, 2021(1), 6630295.","journal-title":"Journal of Oncology"},{"issue":"12","key":"2133_CR73","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cells8121527","volume":"8","author":"F Morandi","year":"2019","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019). CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies. Cells, 8(12), 1527.","journal-title":"Cells"},{"key":"2133_CR74","doi-asserted-by":"crossref","unstructured":"Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., \u2026Chini, E. N. (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 62(4), 1084\u20131093.","DOI":"10.2337\/db12-1139"},{"key":"2133_CR75","doi-asserted-by":"crossref","unstructured":"Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., \u2026 Zou, B. (2020).NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal transduction and targeted therapy, 5(1), 227.","DOI":"10.1038\/s41392-020-00311-7"},{"key":"2133_CR76","doi-asserted-by":"crossref","unstructured":"Haffner, C. D., Becherer, J. D., Boros, E. E., Cadilla, R., Carpenter, T., Cowan,D., \u2026 Ulrich, J. C. (2015). Discovery, synthesis, and biological evaluation of thiazoloquin(az) olin (on) es as potent CD38 inhibitors. Journal of medicinal chemistry, 58(8), 3548\u20133571.","DOI":"10.1021\/jm502009h"},{"key":"2133_CR77","doi-asserted-by":"crossref","unstructured":"Tarrag\u00f3, M. G., Chini, C. C., Kanamori, K. S., Warner, G. M., Caride, A., de Oliveira,G. C., \u2026 Chini, E. N. (2018). A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell metabolism, 27(5), 1081\u20131095.","DOI":"10.1016\/j.cmet.2018.03.016"},{"key":"2133_CR78","doi-asserted-by":"crossref","unstructured":"Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., \u2026 Byers, L. A. (2018).CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discovery, 8(9), 1156\u20131175.","DOI":"10.1158\/2159-8290.CD-17-1033"},{"key":"2133_CR79","doi-asserted-by":"crossref","unstructured":"Camacho-Pereira, J., Tarrag\u00f3, M. G., Chini, C. C., Nin, V., Escande, C., Warner, G.M., \u2026 Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell metabolism, 23(6), 1127\u20131139.","DOI":"10.1016\/j.cmet.2016.05.006"},{"key":"2133_CR80","doi-asserted-by":"crossref","unstructured":"Morandi, F., Horenstein, A. L., Chillemi, A., Quarona, V., Chiesa, S., Imperatori,A., \u2026 Malavasi, F. (2015). CD56brightCD16\u2009\u2013\u2009NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4\u2009+\u2009T cell proliferation.The Journal of Immunology, 195(3), 965\u2013972.","DOI":"10.4049\/jimmunol.1500591"},{"key":"2133_CR81","doi-asserted-by":"crossref","unstructured":"Dean, I., Lee, C. Y., Tuong, Z. K., Li, Z., Tibbitt, C. A., Willis, C., \u2026 Withers,D. R. (2024). Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nature Communications, 15(1), 683.","DOI":"10.1038\/s41467-024-44789-z"},{"issue":"12","key":"2133_CR82","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cells8121527","volume":"8","author":"F Morandi","year":"2019","unstructured":"Morandi, F., Airoldi, I., Marimpietri, D., Bracci, C., Faini, A. C., & Gramignoli, R. (2019). CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies. Cells, 8(12), 1527.","journal-title":"Cells"},{"key":"2133_CR83","doi-asserted-by":"crossref","unstructured":"Brennan, K., Iversen, K. F., Blanco-Fern\u00e1ndez, A., Lund, T., Plesner, T., & Mc Gee, M. M. (2026). Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma. Journal of Extracellular Vesicles, 15(2), e70213.","DOI":"10.1002\/jev2.70213"},{"key":"2133_CR84","doi-asserted-by":"crossref","unstructured":"Nijhof, I. S., Casneuf, T., Van Velzen, J., van Kessel, B., Axel, A. E., Syed, K.,\u2026 van de Donk, N. W. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, the Journal of the American Society of Hematology, 128(7), 959\u2013970.","DOI":"10.1182\/blood-2016-03-703439"},{"issue":"5","key":"2133_CR85","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022). Anti CD38 monoclonal antibodies for multiple myeloma treatment. Human Vaccines & Immunotherapeutics, 18(5), 2052658.","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"2133_CR86","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wang, H. L., Lautrup, S., Nilsen, H. L., Treebak, J. T., Watne, L. O.,\u2026 Fang, E. F. (2025). Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging, 5(9), 1704\u20131731.","DOI":"10.1038\/s43587-025-00947-6"},{"key":"2133_CR87","doi-asserted-by":"crossref","unstructured":"Basak, S., Colafrancesco, A. M., Hernandez, R. D., Wei, X., McMeekin, L. J., Dang,D., \u2026 Olsen, M. L. (2026). Novel Roles for the Ectoenzyme CD38 in the Maintenance of Transcriptional and Metabolic Homeostasis in Astrocytes. Glia, 74(2), e70112.","DOI":"10.1002\/glia.70112"},{"issue":"4","key":"2133_CR88","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41416-022-02052-6","volume":"128","author":"L Gao","year":"2023","unstructured":"Gao, L., Du, X., Li, J., & Qin, F. X. F. (2023). Evolving roles of CD38 metabolism in solid tumour microenvironment. British Journal of Cancer, 128(4), 492\u2013504.","journal-title":"British Journal of Cancer"},{"key":"2133_CR89","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan, K. A., Chini, C. C., & Chini, E. N. (2019). The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Frontiers in immunology, 10, 1187.","journal-title":"Frontiers in immunology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02133-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:03:17Z","timestamp":1788850997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02133-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":89,"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02133-w","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"21 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}